Nymox Pharmaceutical Corporation [NYMX] moved up 38.89: Why It’s Important


Nymox Pharmaceutical Corporation [NASDAQ: NYMX] closed the trading session at $0.30 on 07/15/22. The day’s price range saw the stock hit a low of $0.2187, while the highest price level was $0.3997. The company report on July 15, 2022 that NYMOX Updates Shareholders.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being positively advanced.

Dr. Paul Averback, President and CEO stated, “The Company is well funded and despite setbacks we have advanced our main projects. We expect to provide important further details this summer and also this fall in Q3 and Q4.”.

The stocks have a year to date performance of -76.92 percent and weekly performance of -26.74 percent. The stock has been moved at -80.26 percent over the last six months. The stock has performed -38.14 percent around the most recent 30 days and changed -77.44 percent over the most recent 3-months.

If compared to the average trading volume of 277.90K shares, NYMX reached to a volume of 9157382 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Nymox Pharmaceutical Corporation [NYMX]:

BioLogic Equity Research have made an estimate for Nymox Pharmaceutical Corporation shares, keeping their opinion on the stock as Sell, with their previous recommendation back on February 15, 2011.

NYMX stock trade performance evaluation

Nymox Pharmaceutical Corporation [NYMX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.74. With this latest performance, NYMX shares dropped by -38.14% in over the last four-week period, additionally sinking by -80.26% over the last 6 months – not to mention a drop of -78.57% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NYMX stock in for the last two-week period is set at 33.79, with the RSI for the last a single of trading hit 35.07, and the three-weeks RSI is set at 33.55 for Nymox Pharmaceutical Corporation [NYMX]. The present Moving Average for the last 50 days of trading for this stock 0.6481, while it was recorded at 0.3287 for the last single week of trading, and 1.3130 for the last 200 days.

Nymox Pharmaceutical Corporation [NYMX]: An insightful look at the core fundamentals

Nymox Pharmaceutical Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.40.

Nymox Pharmaceutical Corporation [NYMX]: Insider Ownership positions

There are presently around $0 million, or 1.40% of NYMX stock, in the hands of institutional investors. The top three institutional holders of NYMX stocks are: BLACKROCK INC. with ownership of 135,485, which is approximately -0.129% of the company’s market cap and around 5.20% of the total institutional ownership; CITIGROUP INC, holding 109,079 shares of the stock with an approximate value of $33000.0 in NYMX stocks shares; and PRIVATE ADVISOR GROUP, LLC, currently with $26000.0 in NYMX stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Nymox Pharmaceutical Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 11 institutional holders increased their position in Nymox Pharmaceutical Corporation [NASDAQ:NYMX] by around 468,199 shares. Additionally, 18 investors decreased positions by around 225,629 shares, while 21 investors held positions by with 550,962 shares. The mentioned changes placed institutional holdings at 1,244,790 shares, according to the latest SEC report filing. NYMX stock had 8 new institutional investments in for a total of 420,291 shares, while 12 institutional investors sold positions of 210,644 shares during the same period.